Study findings indicate therapeutic potential of microbiome-based intervention to restore bile acid balance and promote gut healing in ulcerative colitis.

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

New research shows that mutations in DNMT3A in blood stem cells of frequent blood donors may bolster the production of noncancerous cells.

Findings suggest that better understanding of how sex hormones interact with chronic pain could lead to new approaches to addressing the opioid epidemic.

Given the growing antibiotic resistance crisis, novel ways to target bacterial infections are becoming increasingly important. One potential strategy is to manipulate bacterial genes at the ...

“Today, let’s stand up for science!” cried Harold Varmus, MD, Nobel laureate, former NIH director, and professor of medicine at Weill Cornell Medicine to the hundreds of people gathered in Washington ...

President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...

Researchers suggest a better understanding of the neural basis for thermoregulation during motion sickness may provide ...

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.